

# Josã© Marã-a Pego-Reigosa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8837831/publications.pdf>

Version: 2024-02-01

82  
papers

4,384  
citations

185998

28  
h-index

114278

63  
g-index

86  
all docs

86  
docs citations

86  
times ranked

4537  
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	2.9	1,098
2	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.5	759
3	Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 256-264.	1.6	244
4	Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. <i>Rheumatology</i> , 2008, 47, 1498-1502.	0.9	132
5	Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus Cohort. <i>Arthritis Care and Research</i> , 2015, 67, 1180-1185.	1.5	125
6	Respiratory manifestations of systemic lupus erythematosus: old and new concepts. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 469-480.	1.4	117
7	Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 38-45.	1.6	117
8	Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2018, 20, 100.	1.6	102
9	Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 175-185.	1.6	101
10	Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis. <i>Rheumatology International</i> , 2015, 35, 17-26.	1.5	100
11	Cardiovascular Events in Systemic Lupus Erythematosus. <i>Medicine (United States)</i> , 2015, 94, e1183.	0.4	96
12	Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. <i>Rheumatology</i> , 2010, 49, 960-971.	0.9	94
13	Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 988-990.	0.5	66
14	Prevalencia de enfermedades reumáticas en población adulta en España (estudio EPISER 2016). Objetivos y metodología. <i>Reumatología Clínica</i> , 2019, 15, 90-96.	0.2	63
15	Registro nacional de pacientes con lupus eritematoso sistémico de la Sociedad Española de Reumatología: objetivos y metodología. <i>Reumatología Clínica</i> , 2014, 10, 17-24.	0.2	55
16	Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER). <i>Medicine (United States)</i> , 2016, 95, e2891.	0.4	55
17	Calcium pyrophosphate deposition disease mimicking polymyalgia rheumatica: A prospective followup study of predictive factors for this condition in patients presenting with polymyalgia symptoms. <i>Arthritis and Rheumatism</i> , 2005, 53, 931-938.	6.7	52
18	Efficacy and Safety of Nonbiologic Immunosuppressants in the Treatment of Nonrenal Systemic Lupus Erythematosus: A Systematic Review. <i>Arthritis Care and Research</i> , 2013, 65, 1775-1785.	1.5	50

#	ARTICLE	IF	CITATIONS
19	Comprehensive Description of Clinical Characteristics of a Large Systemic Lupus Erythematosus Cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) With Emphasis on Complete Versus Incomplete Lupus Differences. <i>Medicine (United States)</i> , 2015, 94, e267.	0.4	48
20	The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis. <i>Rheumatology</i> , 2021, 60, 60-72.	0.9	42
21	Biological therapy for systemic vasculitis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 542-557.	1.6	41
22	Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort. <i>Arthritis Research and Therapy</i> , 2018, 20, 280.	1.6	40
23	Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7100.	1.8	39
24	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.5	37
25	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.5	35
26	Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries?. <i>Rheumatology</i> , 2020, 59, 2556-2562.	0.9	32
27	Consenso de la Sociedad EspaÃ±ola de ReumatologÃ­a sobre el uso de terapias biolÃ³gicas en el lupus eritematoso sistÃ©mico. <i>ReumatologÃ­a ClÃ­nica</i> , 2013, 9, 281-296.	0.2	31
28	Comorbidities (excluding lymphoma) in SjÃ¶rgren's syndrome. <i>Rheumatology</i> , 2021, 60, 2075-2084.	0.9	30
29	Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. <i>Rheumatology</i> , 2010, 49, 691-696.	0.9	29
30	Efficacy of Raynaud's phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review. <i>Rheumatology International</i> , 2015, 35, 1447-1459.	1.5	29
31	Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry. <i>Rheumatology</i> , 2016, 55, 1243-1250.	0.9	28
32	Comorbidities in Patients With Primary SjÃ¶rgren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study. <i>Arthritis Care and Research</i> , 2017, 69, 38-45.	1.5	27
33	Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2008, 48, 573-575.	0.9	23
34	Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER). <i>Rheumatology</i> , 2021, 60, 1793-1803.	0.9	23
35	Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 720-729.	0.8	20
36	Prevalencia de artrosis sintomÃ¡tica en EspaÃ±a: Estudio EPISER2016. <i>ReumatologÃ­a ClÃ­nica</i> , 2021, 17, 461-470.	0.2	20

#	ARTICLE	IF	CITATIONS
37	CD26 Expression on T Helper Populations and sCD26 Serum Levels in Patients with Rheumatoid Arthritis. PLoS ONE, 2015, 10, e0131992.	1.1	19
38	Bacteremia in Systemic Lupus Erythematosus in Patients from a Spanish Registry: Risk Factors, Clinical and Microbiological Characteristics, and Outcomes. Journal of Rheumatology, 2020, 47, 234-240.	1.0	19
39	Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality. Lupus, 2020, 29, 1556-1565.	0.8	19
40	Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review. British Journal of Clinical Pharmacology, 2022, 88, 1529-1550.	1.1	19
41	Semaphorin4A-Plexin D1 Axis Induces Th2 and Th17 While Represses Th1 Skewing in an Autocrine Manner. International Journal of Molecular Sciences, 2020, 21, 6965.	1.8	16
42	Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study*. Reumatología Clínica (English) Tj ETQq0 0.0,rgBT /Overlock 10	0.2	16
43	Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis. International Journal of Molecular Sciences, 2021, 22, 1263.	1.8	16
44	Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort. BMJ Open, 2019, 9, e028697.	0.8	15
45	Monocytes and Macrophages in Spondyloarthritis: Functional Roles and Effects of Current Therapies. Cells, 2022, 11, 515.	1.8	15
46	Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy. Expert Opinion on Investigational Drugs, 2008, 17, 31-41.	1.9	14
47	Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER). Seminars in Arthritis and Rheumatism, 2019, 48, 1025-1029.	1.6	14
48	Juvenile- and adult-onset systemic lupus erythematosus: a comparative study in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER). Clinical and Experimental Rheumatology, 2017, 35, 1047-1055.	0.4	14
49	Anti-CD26 autoantibodies are involved in rheumatoid arthritis and show potential clinical interest. Clinical Biochemistry, 2017, 50, 903-910.	0.8	13
50	National Registry of Patients With Systemic Lupus Erythematosus of the Spanish Society of Rheumatology: Objectives and Methodology. Reumatología Clínica (English Edition), 2014, 10, 17-24.	0.2	11
51	Hormonal Dependence and Cancer in Systemic Lupus Erythematosus. Arthritis Care and Research, 2020, 72, 216-224.	1.5	11
52	SER Consensus Statement on the Use of Biologic Therapy for Systemic Lupus Erythematosus. Reumatología Clínica (English Edition), 2013, 9, 281-296.	0.2	10
53	Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry. Rheumatology, 2020, 59, 2043-2051.	0.9	10
54	Central Role of Semaphorin 3B in a Serum-induced Arthritis Model and Reduced Levels in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2022, 74, 972-983.	2.9	9

#	ARTICLE	IF	CITATIONS
55	Angiopoietin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9544.	1.8	8
56	Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study. <i>RMD Open</i> , 2021, 7, e001925.	1.8	8
57	Clinical practice guidelines for systemic lupus erythematosus: Recommendations for general clinical management. <i>Medicina ClÃnica (English Edition)</i> , 2016, 146, 413.e1-413.e14.	0.1	7
58	Desarrollo de una aplicaciÃ³n para telÃ©fonos mÃ³viles (app) basada en la colaboraciÃ³n Sociedad EspaÃ±ola de ReumatologÃa/Sociedad EspaÃ±ola de Medicina de Familia y Comunitaria para derivaciÃ³n de enfermedades autoinmunes sistÃ©micas. <i>ReumatologÃa ClÃnica</i> , 2020, 16, 373-377.	0.2	7
59	Content analysis of Twitter in relation to biological treatments for chronic inflammatory arthropathies: an exploratory study. <i>European Journal of Hospital Pharmacy</i> , 2019, 26, 124-128.	0.5	6
60	Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature. <i>ReumatologÃa ClÃnica</i> , 2019, 15, 34-42.	0.2	6
61	Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 657-662.	1.6	5
62	Analysis of the implementation of an innovative IT solution to improve waiting times, communication with primary care and efficiency in Rheumatology. <i>BMC Health Services Research</i> , 2022, 22, 60.	0.9	5
63	Medication persistence on biological therapies prescribed for the treatment of chronic inflammatory arthropathies: a real-world data study. <i>European Journal of Hospital Pharmacy</i> , 2021, 28, e47-e50.	0.5	4
64	Prevalence and factors associated with osteoporosis and fragility fractures in patients with primary SjÃ¶gren syndrome. <i>Rheumatology International</i> , 2020, 40, 1259-1265.	1.5	4
65	Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?. <i>Rheumatology</i> , 2021, 60, 5329-5336.	0.9	4
66	Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151946.	1.6	4
67	How to investigate: Suspected systemic rheumatic diseases in patients presenting with muscle complaints. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101437.	1.4	3
68	Distinctive CD26 Expression on CD4 T-Cell Subsets. <i>Biomolecules</i> , 2021, 11, 1446.	1.8	3
69	Adherence to biological therapies in patients with chronic inflammatory arthropathies. <i>Farmacia Hospitalaria</i> , 2019, 43, 134-139.	0.6	3
70	Study of Plasma Anti-CD26 Autoantibody Levels in a Cohort of Treatment-NaÃve Early Arthritis Patients. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2022, 70, 12.	1.0	2
71	What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. <i>Lupus Science and Medicine</i> , 2021, 8, e000506.	1.1	1
72	ValoraciÃ³n del riesgo de fractura en poblaciÃ³n general en EspaÃ±a mediante el algoritmo FRAXÂ®: Estudio EPISER2016. <i>Medicina ClÃnica</i> , 2020, 154, 163-170.	0.3	1

#	ARTICLE	IF	CITATIONS
73	Comment on: Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries? Reply. <i>Rheumatology</i> , 2021, 60, e120-e121.	0.9	1
74	Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study. <i>Rheumatology</i> , 2022, 62, 217-224.	0.9	1
75	Autoimmune diseases. <i>Medicine</i> , 2008, 36, 279-283.	0.2	0
76	Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain. <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 245-249.	0.2	0
77	OUP accepted manuscript. <i>Rheumatology</i> , 2021, 60, e455.	0.9	0
78	Myo-Spain: Registro de pacientes con miopatía inflamatoria idiopática de España. <i>Metodología Reumatológica Clínica</i> , 2021, , .	0.2	0
79	Aportaciones del registro de lupus de la Sociedad Española de Reumatología (RELESSER) al conocimiento del lupus eritematoso sistémico en España. <i>Reumatología Clínica</i> , 2021, 17, 245-249.	0.2	0
80	Biological therapy safety in chronic inflammatory arthropathy patients. <i>European Journal of Rheumatology</i> , 2020, 7, 53-59.	1.3	0
81	Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables. <i>Rheumatology International</i> , 2021, , 1.	1.5	0
82	Direct costs in patients with chronic inflammatory arthropathies on biological therapy: a real-world data study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 736-745.	0.4	0